The Glioblastoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Glioblastoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Glioblastoma Market.

Some of the key takeaways from the Glioblastoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Glioblastoma treatment therapies with a considerable amount of success over the years. 
• Glioblastoma companies working in the treatment market are Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis Pharmaceuticals, Denovo Biopharma, Celgene Corporation, Oncoceutics, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Voronoi, and others, are developing therapies for the Glioblastoma treatment 

• Emerging Glioblastoma therapies in the different phases of clinical trials are- CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, ONC201, VAL-083, Paxalisib, VBI-1901, VRN-01, and others are expected to have a significant impact on the Glioblastoma market in the coming years.   
• In October 2023, The FDA granted ABM Therapeutics a fast track designation to “facilitate the development and expedite the review of medicines to treat serious conditions and fill an unmet medical need” after previously designating ABM-1310 as an orphan drug to treat malignant gliomas, including glioblastoma.
• In September 2023, Chinese biotechnology company Ascletis Pharma enrolled all 120 patients in its Phase III clinical trial of ASC40 in combination with bevacizumab for the treatment of recurrent glioblastoma (rGBM).
• In September 2023, Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways, today announced that its license partner, Ascletis Bioscience Co. Ltd. (Ascletis), has enrolled 120 patients in its Phase 3 registration clinical trial of denifanstat combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). Ascletis anticipates that this number of study subjects will provide sufficient events for its planned interim analysis of progression-free survival (PFS). Denifanstat is an oral, selective small molecule inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). Sagimet licensed the rights to develop and commercialize denifanstat in the People’s Republic of China, Hong Kong, Macau and Taiwan to Ascletis in January 2019.
• In September 2023, edicenna Therapeutics is approaching other regulatory agencies outside the US to expand its upcoming Phase III trial in recurrent glioblastoma investigating MDNA55, CEO Dr Fahar Merchant told Clinical Trials Arena.

Glioblastoma Overview

Glioblastoma (GBM), commonly known as a grade IV astrocytoma, is an aggressive brain tumour that grows quickly. Nearby brain tissue gets invaded, but it typically does not spread to distant organs. GBMs can develop from lower-grade astrocytomas or develop from new brain tumours.

Get a Free Sample PDF Report to know more about Glioblastoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight

Emerging Glioblastoma Drugs Under Different Phases of Clinical Development Include:

• CT 179: Curtana Pharmaceuticals
• PRT3645: Prelude Therapeutics
• CD200AR L: OX2 Therapeutics
• ADI-PEG 20: Polaris Group
• CM93: Crimson Biopharm
• Berubicin: CNS Pharmaceuticals
• SurVaxM: MimiVax
• BPM31510: Berg, LLC
• ASC40: Ascletis Pharmaceuticals
• Enzastaurin: Denovo Biopharma
• Marizomib: Celgene Corporation
• ONC201: Oncoceutics
• VAL-083: Kintara Therapeutics
• Paxalisib: Kazia Therapeutics
• VBI-1901: VBI Vaccines
• VRN-01: Voronoi
• VT1021: Vigeo Therapeutics
• Varlilumab: Celldex Therapeutics
• Debio 0123: Debiopharma 

Glioblastoma Route of Administration

Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Glioblastoma Molecule Type

Glioblastoma Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Glioblastoma Pipeline Therapeutics Assessment

• Glioblastoma Assessment by Product Type
• Glioblastoma By Stage and Product Type
• Glioblastoma Assessment by Route of Administration
• Glioblastoma By Stage and Route of Administration
• Glioblastoma Assessment by Molecule Type
• Glioblastoma by Stage and Molecule Type

DelveInsight’s Glioblastoma Report covers around 210+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Glioblastoma product details are provided in the report. Download the Glioblastoma pipeline report to learn more about the emerging Glioblastoma therapies

Some of the key companies in the Glioblastoma Therapeutics Market include:

Key companies developing therapies for Glioblastoma are – Pfizer, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Accendatech, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others.

Glioblastoma Pipeline Analysis:

The Glioblastoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Glioblastoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma Treatment.
• Glioblastoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Glioblastoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioblastoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Glioblastoma drugs and therapies

Glioblastoma Pipeline Market Drivers

• Rising incidence of Glioblastoma multiforme, improving Healthcare Infrastructure• Demand for New and Effective Drugs are some of the important factors that are fueling the Glioblastoma Market.

Glioblastoma Pipeline Market Barriers

• However, aggressive nature of GBM and the complexity of targeting the central nervous system, the current standard of care for patients with newly diagnosed glioblastoma has limited effectiveness and a second line has not been established and other factors are creating obstacles in the Glioblastoma Market growth.

Scope of Glioblastoma Pipeline Drug Insight    

• Coverage: Global
• Key Glioblastoma Companies: Curtana Pharmaceuticals, Prelude Therapeutics, OX2 Therapeutics, Polaris Group, Crimson Biopharm, CNS Pharmaceuticals, MimiVax, Berg, LLC, Ascletis Pharmaceuticals, Denovo Biopharma, Celgene Corporation, Oncoceutics, Kintara Therapeutics, Kazia Therapeutics, VBI Vaccines, Voronoi, and others
• Key Glioblastoma Therapies: CT 179, PRT3645, CD200AR L, ADI-PEG 20, CM93, Berubicin, SurVaxM, BPM31510, ASC40, Enzastaurin, Marizomib, ONC201, VAL-083, Paxalisib, VBI-1901, VRN-01, and others
• Glioblastoma Therapeutic Assessment: Glioblastoma current marketed and Glioblastoma emerging therapies
• Glioblastoma Market Dynamics: Glioblastoma market drivers and Glioblastoma market barriers 

Request for Sample PDF Report for Glioblastoma Pipeline Assessment and clinical trials

Table of Contents 

1. Glioblastoma Report Introduction

2. Glioblastoma Executive Summary

3. Glioblastoma Overview

4. Glioblastoma- Analytical Perspective In-depth Commercial Assessment

5. Glioblastoma Pipeline Therapeutics

6. Glioblastoma Late Stage Products (Phase II/III)

7. Glioblastoma Mid Stage Products (Phase II)

8. Glioblastoma Early Stage Products (Phase I)

9. Glioblastoma Preclinical Stage Products

10. Glioblastoma Therapeutics Assessment

11. Glioblastoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Glioblastoma Key Companies

14. Glioblastoma Key Products

15. Glioblastoma Unmet Needs

16 . Glioblastoma Market Drivers and Barriers

17. Glioblastoma Future Perspectives and Conclusion

18. Glioblastoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services